Avexitide is a first-in-class GLP-1 receptor antagonist and FDA Breakthrough Therapy with highly statistically significant data and well-tolerated safety profile replicated across multiple clinical trials. Phase 3 program in avexitide in post-bariatric hypoglycemia (PBH) expected to begin in Q1 2025.
More moments
like this
In memory of Mick, a husband and father, who was a gifted tattoo artist and musician.
Everything we do at Amylyx is centered around those living with diseases with high unmet needs and their loved ones. We are on a mission to discover and develop innovative treatments and to help support and create more moments for these communities.
In memory of Mick, a husband and father, who was a gifted tattoo artist and musician.
And this
Kristina, living with ALS
Kristina, living with ALS
And this
In memory of Eric, a husband and father, who was a courageous skydiver and Army veteran.
Because these are the moments that truly matter.
In memory of Eric, a husband and father, who was a courageous skydiver and Army veteran.
Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation
Positive topline results from Phase 2 HELIOS trial announced
The open-label Phase 2 HELIOS trial of AMX0035 in 12 adults living with Wolfram syndrome showed improvement in pancreatic function, as measured by C-peptide response after 24 weeks of treatment, in contrast to the progression expected in this disease. Similar overall improvements or stabilization were also observed across all secondary endpoints.
In pursuit of more
Our ongoing commitment to discovery carries with it a responsibility to be transparent, set realistic expectations, and work together to make an impact. Learn more about our unique culture, approach to clinical trials and more.
Our ongoing commitment to discovery carries with it a responsibility to be transparent, set realistic expectations, and work together to make an impact. Learn more about our unique culture, approach to clinical trials and more.
Driven by People
“« When you're diagnosed with ALS [amyotrophic lateral sclerosis], you're no longer on the human clock, you're on the ALS clock. Every passing day is a lifetime to an ALS patient, and ALS patients don't have time to wait.” »
Cali, ALS caregiver
“« I feel like Amylyx is a very different company than most that I work with and truly seems like a company that cares, with a big heart, but further than that is they have a fierceness in them and they’re not going to back down from so many of the obstacles that people living with ALS have been facing.” »
Sandy, Person with ALS
“« You require help, that in the years prior, you never needed — where people have to change their lifestyle, to make your lifestyle. So, it doesn't just affect you, it affects the ones around you.” »
Greg, Person living with ALS
In the Moment
Latest News
Next
An error has occurred. Please refresh the page and retry.
Keep in touch
To stay up to date on Amylyx news, click subscribe.